LGD-4033, is a selective androgen receptor modulator (SARM) developed for its potential in treating muscle atrophy, particularly in individuals with hip fractures. It has also been investigated for its use in conditions like cachexia, hypogonadism, and osteoporosis, although development for these indications has been discontinued.
The molecule binds to androgen receptors with high affinity and selectivity, exhibiting anabolic effects in muscle and bone while showing partial agonist or antagonistic effects in the prostate gland.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Ligandrol, LGD-4033, VK-5211 |
|---|---|
| IUPAC Name | 4-[(2R)-2-[(1R)-2, 2, 2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| CAS | 1165910-22-4 |
| Molecular Weight | 338.25 |
| Molecular Formula | C14H12F6N2O |
| SMILES | C1C[C@@H](N(C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)[C@H](C(F)(F)F)O |